Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2708524
Reference Type
Journal Article
Title
The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO
Author(s)
Zhang, D; Fa, HB; Zhou, JT; Li, S; Diao, XW; Yin, W
Year
2015
Is Peer Reviewed?
Yes
Journal
Clinical Radiology
ISSN:
0009-9260
EISSN:
1365-229X
Volume
70
Issue
1
Page Numbers
74-80
Language
English
PMID
25459675
DOI
10.1016/j.crad.2014.09.019
Web of Science Id
WOS:000347867300011
URL
http://
://WOS:000347867300011
Exit
Abstract
AIM:
To detect the β-amyloid plaques (Aβ) in a rat model of Alzheimer's disease (AD) using superparamagnetic iron oxide nanoparticles coated with 1,1-dicyano-2-[6-(dimethylamino)-naphthalene-2-yl] propene carboxyl derivative (DDNP-SPIO).
MATERIALS AND METHODS:
DDNP-SPIO was prepared in a previous trial. The binding affinity of DDNP-SPIO to Aβ was tested using fluorescence spectrophotometry in vitro. In vivo, five AD rats and five non-AD rats were intravenously injected with DDNP-SPIO at a dose of 76 μmol Fe/kg. Coronal T2*-weighted images were collected at baseline and repeated at 10, 30, and 60 min post-injection. Enhancement features of the two groups were analysed. After imaging, brain specimens were resected for Congo red and Prussian blue staining to assess the binding of DDNP-SPIO to Aβ deposits.
RESULTS:
In vitro experiments indicated that the DDNP-SPIO nanoparticles displayed high binding affinities towards Aβ with a Kd value of 29.4 nmol/l. A significant decrease in SI was detected in the hippocampal area of AD rats after intravenous injection of the nanoparticles, but not in non-AD rats. The measurement of the percentage signal loss decreased to 52% in AD rats. In non-AD rats, only 10% signal loss was observed. There was a significant difference between the two groups (t = 4.533, p < 0.05). The signal decrease resulted from the binding of the DDNP-SPIO nanoparticles to the Aβ plaques, which was identified with Congo red and Prussian blue staining.
CONCLUSION:
The DDNP-SPIO nanoparticles could potentially be used for visualizing Aβ plaques, which may be helpful for diagnosing the early stages of AD and monitoring the effects of drug therapy.
Tags
IRIS
•
Naphthalene
Previous HERO references
Database Searches
PubMed
Combined data set
Data set for title/abstract screening
Excluded - PECO criteria not met (TIAB)
•
Naphthalene (2021 Evidence mapping publication)
Previous HERO references
Database Searches
PubMed
Combined data set
Data set for title/abstract screening
Excluded – PECO criteria not met
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity